Bulletin
Investor Alert

Syneos Health Inc. Cl A

NAS: SYNH

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 18, 2020, 4:32 p.m.

/zigman2/quotes/207981284/composite

$

54.20

Change

+0.0017 +0.0031%

Volume

Volume 46,148

Quotes are delayed by 20 min

/zigman2/quotes/207981284/composite

Previous close

$ 54.74

$ 54.20

Change

-0.54 -0.99%

Day low

Day high

$53.96

$55.64

Open

52 week low

52 week high

$30.02

$74.25

Open

Company Description

Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning P...

Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Valuation

P/E Current

43.36

P/E Ratio (with extraordinary items)

30.42

P/E Ratio (without extraordinary items)

47.58

Price to Sales Ratio

1.34

Price to Book Ratio

2.04

Price to Cash Flow Ratio

19.61

Enterprise Value to EBITDA

14.98

Enterprise Value to Sales

1.93

Total Debt to Enterprise Value

0.32

Efficiency

Revenue/Employee

194,826.00

Income Per Employee

5,469.00

Receivables Turnover

3.65

Total Asset Turnover

0.64

Liquidity

Current Ratio

1.03

Quick Ratio

1.03

Cash Ratio

0.11

Profitability

Gross Margin

16.84

Operating Margin

7.30

Pretax Margin

2.18

Net Margin

2.81

Return on Assets

1.78

Return on Equity

4.46

Return on Total Capital

5.87

Return on Invested Capital

2.29

Capital Structure

Total Debt to Total Equity

96.37

Total Debt to Total Capital

49.08

Total Debt to Total Assets

39.17

Long-Term Debt to Equity

92.61

Long-Term Debt to Total Capital

47.16

Officers and Executives

Name Age Officer Since Title
Mr. Alistair John Macdonald 49 2010 Executive Vice President-Strategic Development
Mr. Jason Michael Meggs 43 2018 Chief Financial Officer & Executive Vice President
Ms. Michelle Keefe - 2017 President-Commercial Solutions
Mr. Paul D. Colvin 49 2018 President-Clinical Solutions
Mr. Neil Ferguson - 2018 Chief Business Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/03/2020 Alistair John Macdonald
Chief Executive Officer; Director
10,289   Disposition at $65.07 per share. 669,505
08/03/2020 Alistair John Macdonald
Chief Executive Officer; Director
4,178   Derivative/Non-derivative trans. at $65.06 per share. 271,820
07/15/2020 Alistair John Macdonald
Chief Executive Officer; Director
9,467   Disposition at $60.14 per share. 569,345
07/15/2020 Alistair John Macdonald
Chief Executive Officer; Director
9,467   Disposition at $60.14 per share. 569,345
07/15/2020 Alistair John Macdonald
Chief Executive Officer; Director
18,934   Disposition at $60.14 per share. 1,138,690
07/15/2020 Alistair John Macdonald
Chief Executive Officer; Director
9,467   Derivative/Non-derivative trans. at $16.06 per share. 152,040
07/15/2020 Alistair John Macdonald
Chief Executive Officer; Director
9,467   Derivative/Non-derivative trans. at $16.06 per share. 152,040
07/15/2020 Alistair John Macdonald
Chief Executive Officer; Director
18,934   Derivative/Non-derivative trans. at $16.06 per share. 304,080
07/14/2020 Alistair John Macdonald
Chief Executive Officer; Director
373   Disposition at $59.15 per share. 22,062
07/14/2020 Alistair John Macdonald
Chief Executive Officer; Director
4,800   Disposition at $58.64 per share. 281,472
07/14/2020 Alistair John Macdonald
Chief Executive Officer; Director
5,173   Derivative/Non-derivative trans. at $10.57 per share. 54,678
07/13/2020 Alistair John Macdonald
Chief Executive Officer; Director
3,655   Disposition at $58.21 per share. 212,757
07/13/2020 Alistair John Macdonald
Chief Executive Officer; Director
3,655   Derivative/Non-derivative trans. at $10.57 per share. 38,633
07/06/2020 Michelle Keefe
Pres., Commercial Solutions
1,500   Disposition at $59.11 per share. 88,665
07/06/2020 John M. Dineen
Director
8,691   Acquisition at $59.11 per share. 513,725
05/27/2020 Thomas H. Lee Partners LP
Director
2,803   Award at $0 per share. 0
05/27/2020 Thomas H. Lee Partners LP
Director
2,803   Award at $0 per share. 0
05/27/2020 Thomas H. Lee Partners LP
Director
2,803   Award at $0 per share. 0
05/27/2020 Thomas H. Lee Partners LP
Director
2,803   Award at $0 per share. 0
05/27/2020 John M. Dineen
Director
2,803   Award at $62.43 per share. 174,991
05/27/2020 Kenneth F. Meyers
Director
2,803   Award at $62.43 per share. 174,991
05/27/2020 Matthew E. Monaghan
Director
2,803   Award at $62.43 per share. 174,991
05/27/2020 William E. Klitgaard
Director
2,803   Award at $62.43 per share. 174,991
05/27/2020 Linda A. Harty
Director
2,803   Award at $62.43 per share. 174,991
05/27/2020 Bernadette M. Connaughton
Director
2,803   Award at $62.43 per share. 174,991
05/20/2020 Michelle Keefe
Pres., Commercial Solutions
2,500   Disposition at $60 per share. 150,000
04/20/2020 Robert Alan Parks
EVP, Chief Accounting Officer
3,588   Disposition at $49.65 per share. 178,144
04/20/2020 Robert Alan Parks
EVP, Chief Accounting Officer
377   Award at $44.48 per share. 16,768
03/20/2020 Jason Michael Meggs
Chief Financial Officer
45   Acquisition at $36 per share. 1,620
03/20/2020 Jason Michael Meggs
Chief Financial Officer
3,510   Acquisition at $36.75 per share. 128,992
03/19/2020 Paul D. Colvin
Pres., Clinical Solutions
1,300   Acquisition at $36.65 per share. 47,645
/news/latest/company/us/synh

MarketWatch News on SYNH

  1. 30 momentum stocks that are actually cheap enough to buy

    3:23 p.m. Dec. 12, 2019

    - Michael Brush

  2. Syneos Health stock price target raised to $57 vs.s $53.50 at UBS, 'overhang removed' after SEC probe

    10:29 a.m. Aug. 29, 2019

    - Ciara Linnane

  3. Syneos Health downgraded to neutral from buy at UBS

    10:12 a.m. March 20, 2019

    - Tomi Kilgore

  4. Syneos Health started at buy with $60 stock price target at UBS

    3:14 p.m. Oct. 9, 2018

    - Tomi Kilgore

  5. Elliott Associates Thinks It Can Make Nielsen Click

    3:14 p.m. Aug. 20, 2018

    - Barron's Online

  6. Here are Wall Street’s 19 favorite mid-cap stocks for 2018

    8:30 a.m. Dec. 8, 2017

    - Philip van Doorn

  7. Healthcare Stocks: Calm After The Storm?

    11:16 a.m. Aug. 1, 2017

    - Barrons Blogs

  8. INC Research stock price target raised to $67 from $51 at Raymond James

    8:23 a.m. June 8, 2017

    - Tomi Kilgore

  9. INC Research upgraded to overweight from sector weight at KeyBanc Capital

    7:25 a.m. June 5, 2017

    - Tomi Kilgore

  10. INC Research stock price target raised to $67 vs. $48 at SunTrust Robinson Humphrey

    7:31 a.m. May 31, 2017

    - Ciara Linnane

  11. INC Research upgraded to buy at SunTrust Robinson Humphrey

    7:30 a.m. May 31, 2017

    - Ciara Linnane

  12. Starboard Value Sees Possible Sale of Parexel

    1:23 a.m. May 20, 2017

    - Barron's Online

  13. INC Research upgraded to outperform from neutral at RW Baird

    7:29 a.m. May 11, 2017

    - Tomi Kilgore

  14. Stock winners and losers — Nvidia rockets and Yelp tumbles

    11:33 a.m. May 10, 2017

    - Philip van Doorn

  15. Pain may be in store for the S&P 500, says Goldman

    8:32 a.m. Sept. 13, 2016

    - Ryan Vlastelica

  16. Loading more headlines...
/news/nonmarketwatch/company/us/synh

Other News on SYNH

  1. Syneos Health prices secondary offering

    9:10 a.m. Sept. 16, 2020

    - Seeking Alpha

  2. Notable earnings before Thursday's open

    1:25 p.m. Aug. 5, 2020

    - Seeking Alpha

  3. Syneos Health: A Stable CRO With A Strategic COVID-19 Plan

    11:10 a.m. July 20, 2020

    - Seeking Alpha

  4. Top Insider Buys Highlight for the Week of July 10

    1:46 p.m. July 11, 2020

    - GuruFocus.com

  5. Invitae (NVTA) Looks Good: Stock Adds 5.8% in Session

    8:42 a.m. June 22, 2020

    - Zacks.com

  6. Senseonics Holdings (SENS) Catches Eye: Stock Jumps 5.7%

    9:38 a.m. June 19, 2020

    - Zacks.com

  7. Allscripts (MDRX) Looks Good: Stock Adds 9.1% in Session

    8:43 a.m. June 16, 2020

    - Zacks.com

  8. 10x Genomics (TXG) Looks Good: Stock Adds 6.2% in Session

    8:39 a.m. June 16, 2020

    - Zacks.com

  9. Loading more headlines...

At a Glance

Syneos Health, Inc.

1030 Sync Street

Morrisville, North Carolina 27560-5468

Phone

1 9198769300

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$4.68B

Net Income

$131.26M

2019 Sales Growth

6.5%

Employees

24,000

/news/pressrelease/company/us/synh

Press Releases on SYNH

  1. Syneos Health Announces Secondary Offering of Common Stock

    11:03 p.m. Sept. 15, 2020

    - GlobeNewswire

  2. Syneos Health Announces Secondary Offering of Common Stock

    11:03 p.m. Sept. 15, 2020

    - GlobeNewswire

  3. Parabolic SAR Signals Bullish US Stocks: $MRTX $GNTX $SYNH

    8:29 a.m. Sept. 1, 2020

    - The Market Signal

  4. Allied Healthcare Staffing Market Global Outlook and Growth Forecast 2026

    8:56 a.m. Aug. 20, 2020

    - Market Insight Reports

  5. Syneos Health Reports Second Quarter 2020 Results

    6:55 a.m. Aug. 6, 2020

    - GlobeNewswire

  6. Syneos Health Reports Second Quarter 2020 Results

    6:15 a.m. Aug. 6, 2020

    - GlobeNewswire

  7. Loading more headlines...
Link to MarketWatch's Slice.